Kath Meely

Risk Adaption in Clinical Trials of Investigational Medicinal Products (CTIMPs)

Kath Meely, 16 November 2017 - Compliance matters, Good clinical practice

MHRA are actively promoting a risk proportionate approach to CTIMPs

Clinical Trials Regulations – have your say

Kath Meely, 1 August 2016 - Compliance matters, Good clinical practice

There are currently four consultations on guidance documents that have been developed in preparation for the implementation of the Clinical Trial Regulation (EU) No 536/2014. The MHRA GCP Inspectorate encourages you to take time to review these.

About the MHRA Inspectorate Blog

This blog shares the work of the Medicines and Healthcare products Regulatory Agency (MHRA) Inspectorate, by inspectors and those the Inspectorate works with.

Find out more

Categories

Follow us on social media

• MHRA Twitter
• MHRA Medicines Twitter
• LinkedIn company page

Sign up and manage updates

• Email
• Atom

Printing Posts

You can print blog posts using the keyboard shortcuts "Control P" or "Command P".

Other MHRA Blogs

MedRegs

Comments and moderation

Read our guidelines

Recent posts

• DSUR Submissions and Fees are Changing from 1 June 2024
• Pharmacovigilance unravelled: highlights of the 2024 MHRA GPvP Symposium
• Pilot GMP Single Inspection Program
• MHRA Pharmacovigilance Symposium 2024
• Guidance updates on to how to notify the MHRA of changes to the PV System